AVANOS MEDICAL, INC.AVNSEarnings & Financial Report
Avanos Medical, Inc. is a medical technology company making clinical medical devices. The company consists of two franchises – Pain Management and Chronic Care – that address reducing the use of opioids while helping patients recover faster and preventing infection.
Revenue
$171.7M
Gross Profit
$95.6M
Operating Profit
$6.3M
Net Profit
$1.8M
Gross Margin
55.7%
Operating Margin
3.7%
Net Margin
1.0%
YoY Growth
1.4%
EPS
$0.04
AVANOS MEDICAL, INC. Q2 FY2024 Financial Summary
AVANOS MEDICAL, INC. reported revenue of $171.7M (up 1.4% YoY) for Q2 FY2024, with a net profit of $1.8M (up 102.6% YoY) (1.0% margin). Cost of goods sold was $76.1M, operating expenses totaled $89.3M.
Key Financial Metrics
| Total Revenue | $171.7M |
|---|---|
| Net Profit | $1.8M |
| Gross Margin | 55.7% |
| Operating Margin | 3.7% |
| Report Period | Q2 FY2024 |
Revenue Breakdown
AVANOS MEDICAL, INC. Q2 FY2024 revenue of $171.7M breaks down across 4 segments, led by Digestive Health at $97.7M (56.9% of total).
| Segment | Revenue | % of Total |
|---|---|---|
| Digestive Health | $97.7M | 56.9% |
| Interventional Pain | $41.7M | 24.3% |
| Surgical Pain And Recovery | $32.3M | 18.8% |
| Diros Technology Inc | $5.1M | 3.0% |
AVANOS MEDICAL, INC. Revenue by Segment — Quarterly Trend
AVANOS MEDICAL, INC. revenue by segment across the last 4 reported quarters, showing how each business line (such as Digestive Health and Interventional Pain) has evolved quarter over quarter.
| Segment | Q4 FY2025 | Q3 FY2025 | Q2 FY2025 | Q1 FY2025 |
|---|---|---|---|---|
| Surgical Pain And Recovery | $24.7M | $24.4M | $25.2M | $24.5M |
AVANOS MEDICAL, INC. Annual Revenue by Year
AVANOS MEDICAL, INC. annual revenue history includes year-by-year totals (for example, 2025 revenue was $701.2M).
| Year | Annual Revenue |
|---|---|
| 2025 | $701.2M |
| 2024 | $687.8M |
| 2023 | $673.3M |
| 2022 | $684.1M |
AVANOS MEDICAL, INC. Quarterly Revenue & Net Profit History
AVANOS MEDICAL, INC. results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 FY2025 | $180.9M | +0.7% | $-1.3M | -0.7% |
| Q3 FY2025 | $177.8M | +4.3% | $-1.4M | -0.8% |
| Q2 FY2025 | $175.0M | +1.9% | $-76.8M | -43.9% |
| Q1 FY2025 | $167.5M | +0.8% | $6.6M | 3.9% |
| Q4 FY2024 | $179.6M | +3.6% | $-397.3M | -221.2% |
| Q3 FY2024 | $170.4M | -0.5% | $4.3M | 2.5% |
| Q2 FY2024 | $171.7M | +1.4% | $1.8M | 1.0% |
| Q1 FY2024 | $166.1M | +4.3% | $-900.0K | -0.5% |
Income Statement
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $166.1M | $171.7M | $170.4M | $179.6M | $167.5M | $175.0M | $177.8M | $180.9M |
| YoY Growth | 4.3% | 1.4% | -0.5% | 3.6% | 0.8% | 1.9% | 4.3% | 0.7% |
Balance Sheet
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $1.66B | $1.66B | $1.66B | $1.15B | $1.11B | $1.04B | $1.07B | $1.07B |
| Liabilities | $433.4M | $435.8M | $426.5M | $325.7M | $268.4M | $262.7M | $289.7M | $295.5M |
| Equity | $1.23B | $1.22B | $1.23B | $828.5M | $839.4M | $776.3M | $778.0M | $778.2M |
Cash Flow
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-8.0M | $27.8M | $23.0M | $57.9M | $25.7M | $6.8M | $14.0M | $28.2M |